Skip to main content

Multi-resistant Gram-negative Bacteria Cause Infection

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Chia Tai TianQing Pharmaceutical Group
1 program
TQD3524PHASE_12 trials
Active Trials
NCT07512596Not Yet Recruiting48Est. Jul 2027
NCT06522945Completed48Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Chia Tai TianQing Pharmaceutical GroupTQD3524
Chia Tai TianQing Pharmaceutical GroupTQD3524

Clinical Trials (2)

Total enrollment: 96 patients across 2 trials

Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria

Start: Apr 2026Est. completion: Jul 202748 patients
Phase 2Not Yet Recruiting

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

Start: Jul 2024Est. completion: Dec 202548 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.